We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Britvic Plc | LSE:BVIC | London | Ordinary Share | GB00B0N8QD54 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
6.50 | 0.75% | 870.00 | 867.00 | 868.00 | 869.00 | 858.50 | 861.50 | 249,677 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Btld & Can Soft Drinks,water | 1.75B | 124M | 0.4969 | 17.47 | 2.17B |
Date | Subject | Author | Discuss |
---|---|---|---|
05/9/2012 10:03 | great news bought in at 270p for the yield after they fell last month | limit up | |
05/9/2012 09:51 | Rumoured where?....got any links? | abcd1234 | |
05/9/2012 09:28 | 400p being rumoured plenty of upside to come | kirk2 | |
05/9/2012 09:25 | The Boards of Britvic and A.G. Barr note the recent press speculation and confirm that, following an approach by A.G. Barr to Britvic, they are in preliminary discussions which may or may not result in an all share merger of A.G. Barr and Britvic. A merger would create one of the leading soft drinks companies in Europe, with a strong portfolio of market leading brands. The combination would have compelling industrial logic and represents an opportunity for both companies to enhance their industry position, and achieve significant synergies and shareholder value. Discussions are at an early stage and, whilst there can be no certainty at this stage that such discussions will conclude successfully, agreement has been reached with respect to certain key aspects of the merger. It is agreed that Britvic shareholders would own 63% and A.G. Barr shareholders 37% of the enlarged group's share capital. The Board of Directors would be drawn equally from the Boards of both companies. Roger White, CEO of A.G. Barr, would become CEO of the combined group and John Gibney, CFO of Britvic, would become CFO. Gerald Corbett, Chairman of Britvic, would become Chairman of the Board of the combined group, and Ronnie Hanna, Chairman of A.G. Barr, would become Deputy Chairman. In addition, the new Board would comprise six other non-executive directors, three nominated from each of Britvic and A.G. Barr. | skinny | |
28/8/2012 13:47 | Britvic is reportedly preparing its first ad campaign for its Robinson's Fruit Shoot children's drink since it was forced into a national product recall in July over safety issues connected with a new bottle cap. A spokesperson for Britvic confirmed that the resupplying of the Fruit Shoot and Fruit Shoot Hydro lines was now "underway" and that a supporting campaign would be released in the coming weeks. However, the campaign "does not make reference" to Britvic's issues with the bottle cap and the spokesperson denied that the push would be positioned to reassure consumers about the brand. The company was forced to stop all sales of its Robinsons Fruit Shoot and Fruit Shoot Hydro drinks when a new design for its plastic "magicap" was found to be unsafe. The company admitted in July that the recall could cost it up to £25m, because it had failed to "speedily" resolve the issue a figure that was much higher than the £1m to £5m cost it had previously predicted. | verngate | |
19/7/2012 12:02 | Well, I certainly took the wrong side of the bet! I still feel that they are overvalued on the basis of an enterprise value of £1.24 Bn (Market cap of £700 and net debt of £543) This year they will struggle to make £35M profit which makes it a rather expensive play to me. | salpara111 | |
19/7/2012 09:18 | well you lot should certainly know the adage about profit warnings "Britvic took a hammering after releasing a profit warning,"they come in threes or worse! | mroalan | |
19/7/2012 09:13 | gap closed | dr_ex | |
13/7/2012 14:16 | I was less bothered by the admittedly very large one off problem. The reason I have gone short is due to the current/future trading with talk of declining sales and customers trading down. They do have a large debt pile to service and I suspect they may be forced to cut the divi to ease pressure there. | salpara111 | |
13/7/2012 10:47 | Agreed, I'm thinking that GFS might be the better short as their problems will likely be longer-lived. Perhaps a pairs trade long of BVIC and short GFS? | hyden | |
13/7/2012 10:32 | Tipped for recovery in today's Questor (Telegraph). Must admit, I was thinking the same myself. If this is a 'one-off' event, earnings will bounce back eventually, although I didn't like the sound of how long it would take. | jeffian | |
12/7/2012 21:33 | Wednesday's Most Followed WEDNESDAY'S MOST FOLLOWED: BRITVIC, SCANCELL HOLDINGS ..... Soft drinks maker Britvic (LON:BVIC) and vaccine developer Scancell Holdings (LON:SCLP) were among the companies that generated the most interest today with both making the list of the most searched for UK stocks on Google Finance. Britvic took a hammering after releasing a profit warning, while Scancell, which had no news out today, surged nearly 10 percent. In a trading update, Britvic revealed that the impact from a product recall announced last week would be worse than initially thought. Last week, the group said there had been safety issues with a new design cap for Fruit Shoot and Fruit Shoot Hydro packs sold in the UK and France and that it was recalling the products. It was initially estimated that these problems would reduce full year pre-tax profits by between £1 and £5 million, however, the overall impact and sales recall is now expected to reach up to £25 million across current and next financial year. Britvic explained today that it has been unable to speedily resolve the issues with the new design cap and it was therefore decided to re-supply in the short term with an alternative in-market proven sports cap. The group added that it expects to increase its output to meet historic levels of demand within six months. Shares in Britvic tumbled 14 percent to 257.6 pence, valuing the group at £623.5 million, while Scancell saw its shares rally nine percent to 18 pence. On message boards, some traders suggested that the buying activity was driven by expectations of news from the ongoing trial of the company's DNA ImmunoBody vaccine SCIB1 for the treatment of melanoma. Back in June, Scancell secured regulatory approval to increase the maximum treatment period from 6 months up to a further 5 years in its Phase I/II clinical trial of SCIB1. The clinical trial of SCIB1 is currently being conducted at five hospital centres in the UK. Over the past month, shares in Scancell have more than doubled, surging from eight pence to Tuesday's close of 16.5 pence. Source: Here's a couple of links about Scancell, one of the hottest stocks at the moment: | northernlass | |
12/7/2012 14:22 | well, I opened my short at 259 so we will see where it is going to go from here. Clearly I am betting on a retracement back to the 200 line. | salpara111 | |
11/7/2012 15:35 | In the 3 years to Oct 2007, gross margin averaged 60.9% (range 61.4-60.0%) In the 3 years to Oct 2010, gross margin averaged 54.4% (range 55.3-54.0%) In the 1 year to Oct 2011 gross margin dropped to 51.4% and they've announced current trading at the bottom end of expectations before including the £15-25m hit to profits Rising debt Oct 2005: -£236m Oct 2006: -£302m Oct 2009: -£451m Oct 2011: -£573m, £43m cash Apr 2012: -£600m, -£6m into overdraft Net trade & payables, pension liability and income tax (Oct 2011): -£177m less £69m derivative gain = other net liabilities of -£108m So net debt & other liabilities of around -£715m (not including inventory). The working capital situation will deteriorate this year with the bottle cap problems and weakening trading requiring further debt drawdowns. Potentially looking at -£750m by end of year. Add the debt to the market cap and its difficult to justify the current share price. | bam bam rubble | |
11/7/2012 15:23 | Salpara - I got the figure from Advfn financials page. No doubt it is out of date! | sat69 | |
11/7/2012 13:24 | Sat69 From the last set of results net debt stands at £534M so not sure where the £1bn comes from. I hold no position and am looking at a potential short. | salpara111 | |
11/7/2012 11:06 | going to 200p | ninja 19 | |
11/7/2012 07:25 | Its getting worst 15-25m now! | jon827 | |
05/7/2012 08:36 | The company carries £1bn of debt and barely services it. I'm expecting a placing or rights issue to take place this year and do not plan to buy until after that has taken place. This recall of fruit-shoot will also make a serious dent to profits at a time the company can ill afford it. Expect further falls in the share price to well below the current 300p. | sat69 | |
03/7/2012 23:01 | Thats a bit out the blue then 1-5m | jon827 | |
08/5/2012 04:58 | BRITVIC INVESTOR INFO Some Video Background Brains Stars In Britvic Ad OVERVIEW OF BRITVIC IRELAND OVERVIEW OF BRITVIC FRANCE WORKPLACE SALES DIGITAL MEDIA TO ENGAGE Britvic held its latest Investor Seminar on Wednesday, 28th March 2012, here is the presentation pdf: Also, Here's a couple of links about SCLP, one of the hottest stocks at the moment: | northernlass | |
25/1/2012 12:44 | That`ll do for me. Luck to all holders. | philanderer | |
01/1/2012 13:56 | Britvic about to enjoy a jolly northwards? The TA suggests it might.. | nofool |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions